[Herbal cake-partitioned moxibustion regulates M1 and M2 macrophage polarization of colonic mucosa in rats with Crohn's disease].

Researchers in China studied whether a traditional Chinese medicine treatment called herbal cake-partitioned moxibustion could help reduce inflammation in rats with Crohn's disease, a chronic inflammatory bowel condition. In this technique, special herbal cakes are placed on acupuncture points and warmed with burning moxa (mugwort herb). The study used 40 rats divided into four groups: normal healthy rats, untreated diseased rats, rats treated with moxibustion, and rats given standard medication (mesalazine). The moxibustion group received treatment at two acupuncture points—Tianshu (ST25) and Qihai (CV6)—once daily for 10 days. Researchers examined colon tissue under microscopes and measured various inflammatory markers and immune cells called macrophages, which play important roles in inflammation. They found that moxibustion treatment significantly improved the condition of the colon tissue and reduced inflammation. Specifically, it decreased harmful M1 macrophages and increased beneficial M2 macrophages, shifting the immune response toward healing. The treatment worked by activating a receptor called α7nAChR, which then suppressed inflammatory pathways and reduced TNF-α, a key inflammatory protein. The moxibustion results were comparable to standard medication. While this animal study shows promising anti-inflammatory effects for Crohn's disease, human clinical trials are needed to confirm these benefits. If you're considering moxibustion for inflammatory bowel conditions, consult with a licensed acupuncturist trained in traditional Chinese medicine techniques.

This animal study (n=40 male SD rats) investigated herbal cake-partitioned moxibustion effects on macrophage polarization in TNBS-induced Crohn's disease. Moxibustion was applied to ST25 and CV6 (2 cones per point, daily for 10 days). Results demonstrated significant improvements in colonic histopathology and ultrastructure compared to untreated disease controls (P<0.01). Treatment upregulated α7nAChR expression while downregulating NF-κB p65 and TNF-α (P<0.01). Flow cytometry and immunofluorescence revealed decreased M1 macrophages and increased M2 macrophages (P<0.05), indicating a shift from pro-inflammatory to anti-inflammatory phenotype. Effects were comparable to mesalazine medication group. The proposed mechanism involves α7nAChR-mediated inhibition of NF-κB activation, promoting M1-to-M2 macrophage polarization and suppressing inflammatory cytokine expression. Clinical implications suggest moxibustion may modulate mucosal immunity through cholinergic anti-inflammatory pathways, warranting human trials for inflammatory bowel disease management.